Meta‐Analysis of Transcriptomic Studies of Blood and Six Brain Regions Identifies a Consensus of 15 Cross‐Tissue Mechanisms in Alzheimer's Disease and Suggests an Origin of Cross‐Study Heterogeneity
Authors:
- Jiahui HouJHJiahui Hou
- Stephen V. FaraoneSFStephen V. Faraone
- Christine Fennema‐NotestineCFChristine Fennema‐Notestine
- Valentina Escott‐PriceVEValentina Escott‐Price
- The Alzheimer'S Disease Neuroimaging InitiativeTIThe Alzheimer'S Disease Neuroimaging Initiative
- 16 December 2024
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 198 (4) , e33019
Abstract
The comprehensive genome‐wide nature of transcriptome studies in Alzheimer's disease (AD) should provide a reliable description of disease molecular states. However, the genes and molecular systems nominated by transcriptomic studies do not always overlap. Even when results do align, it is not clear if those observations represent true consensus across many studies. A couple of sources of variation have been proposed to explain this variability, including tissue‐of‐origin and cohort type, but its basis remains uncertain. To address this variability and extract reliable results, we utilized all publicly available blood or brain transcriptomic datasets of AD, comprised of 24 brain studies with 4007 samples from six different brain regions, and eight blood studies with 1566 samples. We identified a consensus of AD‐associated genes across brain regions and AD‐associated gene‐sets across blood and brain, generalizable machine learning and linear scoring classifiers, and significant contributors to biological diversity in AD datasets. While AD‐associated genes did not significantly overlap between blood and brain, our findings highlighted 15 dysregulated processes shared across blood and brain in AD. The top five most significantly dysregulated processes were DNA replication, metabolism of proteins, protein localization, cell cycle, and programmed cell death. Conversely, addressing the discord across studies, we found that large‐scale gene co‐regulation patterns can account for a significant fraction of variability in AD datasets. Overall, this study ranked and characterized a compilation of genes and molecular systems consistently identified across a large assembly of AD transcriptome studies in blood and brain, providing potential candidate biomarkers and therapeutic targets.Keywords
Funding Information
- National Institute on Aging (R01AG064955, R01AG054002)
This publication has 126 references indexed in Scilit:
- An accurate fully automated panel of plasma biomarkers for Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Genome‐wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathologyAlzheimer's & Dementia, 2020
- Glycogen synthase kinase-3 signaling in Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2020
- Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer’s diseaseActa Neuropathologica, 2019
- Polygenic risk score analysis of pathologically confirmed Alzheimer diseaseAnnals of Neurology, 2017
- Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer’s diseaseJournal of Neural Transmission, 2015
- Role of Cell Cycle Re-Entry in Neurons: A Common Apoptotic Mechanism of Neuronal Cell DeathNeurotoxicity Research, 2011
- Cell Cycle Deregulation in the Neurons of Alzheimer’s Disease2011
- Abortive apoptosis in Alzheimer's diseaseActa Neuropathologica, 2001
- Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of actionNeurotoxicity Research, 2000